In early 2025, our hospital approved a six-bed step-down unit. My first cost comparison said the answer was obvious: don't buy new monitoring equipment.
Let me explain the setup. A step-down unit takes patients who are too stable for the ICU but too unstable for a standard med-surg floor: post-operative patients with airway risk, patients on IV opioids, cardiac and respiratory patients. The kind of people whose condition can quietly slide overnight.
As the person who manages capital procurement at a 320-bed regional hospital, I put two options in a spreadsheet.
Option A: run the unit with the portable spot-check monitors we already own — nurse checks vital signs every four hours, send bloodwork to central lab. Capital cost: $0.
Option B: actually equip it like a step-down unit — six vital signs monitors with capnography modules, plus a point-of-care hematology analyzer in the preparation room. Capital cost: about $91,000.
My first spreadsheet said Option A. Not 'Option A with caveats.' Just: Option A.
I'll be honest with you — I almost closed the file right there. But after six years of procurement work and more than $10 million in tracked equipment purchases, I've learned one thing: be suspicious when the spreadsheet is too unanimous. That's what happened here.
Why I ended up with the Smiths Medical catalog open
Before comparing prices, you have to compare configurations. The spot-check monitors we already owned were never designed for continuous ventilation monitoring. They can measure NIBP, SpO2, temperature and heart rate on demand. Fine tools. But they won't tell you the moment a patient stops breathing effectively.
So I spent an afternoon on the Smiths Medical official website, then pulled up the Smiths Medical catalog to compare monitor platforms for Option B. The catalog was actually the more useful of the two. It shows accessories, optional modules and consumables in one place, which matters more than the base price.
Specifically, I was looking for two things: vital signs monitors with an EtCO2, or capnography, module, and a compact hematology analyzer. If you haven't shopped for a hematology analyzer recently, they're not the giant bench-top machines from ten years ago. The model we configured was roughly the size of a microwave and returned a hemoglobin result in about three minutes.
Cost comparison 1: what each option actually costs to own
Capital cost favors Option A; there's no way around that. But total cost of ownership is a different conversation.
Here's what fell out of my three-year model.
The spot-check route carries real labor costs. With four-hour intervals, one set of vital signs takes about seven minutes per patient, including documentation. For six patients, that's 42 minutes per round, six rounds per day — basically 4.2 hours of nursing time every day just for scheduled vital measurements. At a fully loaded nursing cost near $48 an hour, that's more than $70,000 a year in nursing time spent on a task that continuous monitors can do automatically.
Before you write to me: no, we didn't reduce headcount because of that number. Nurses kept busy with the work that actually needed their judgment. But the number told me the 'free' monitoring option wasn't free.
Option B had hard costs, too: service contracts, capnography accessories, reagents and controls for the analyzer. With the capital amortized over seven years, the real yearly cost was about $35,000. It's less than the spot-check labor number, but $35,000 still looks worse than $0 on a budget page.
So by that comparison, Option A still won. And that's basically where I was until the clinical lead asked a question my spreadsheet couldn't answer.
Cost comparison 2: the space between spot checks
The question was: what happens between checks?
In a six-bed unit, the scheduled interval is four hours. A lot can happen in four hours. But there is one failure mode that kept bothering me: a patient on supplemental oxygen can look completely stable on pulse oximetry while their ventilation quietly falls apart.
This is the point where I had to ask a question I should have asked years ago: what is capnography, and why does it matter outside an operating room?
Capnography measures the CO2 concentration in exhaled breath — end-tidal CO2, or EtCO2 — and displays it as a continuous waveform. Pulse oximetry measures oxygenation. Those two things are not the same.
Here's the clinical scenario that made me understand: a post-surgical patient on opioids can have a depressed respiratory drive. If they start breathing slowly or shallowly, their SpO2 may stay at 95% for quite a while — especially if they're getting a little oxygen through a nasal cannula. But their CO2 is climbing. Pulse oximetry will keep saying 'fine.' Capnography shows the respiratory depression as it happens, breath by breath, typically much earlier than oxygen saturation starts to fall.
The Anesthesia Patient Safety Foundation has made exactly this point for years: when patients are on supplemental oxygen, pulse oximetry is an inadequate monitor for hypoventilation.
What was considered adequate monitoring in 2015 isn't what I'd call defensible in 2025. The fundamentals of nursing haven't changed. But the technology for catching early deterioration has transformed — and the expectation of using it has changed along with it.
Cost comparison 3: what a missed deterioration costs
While the budget was being finalized, the unit opened under Option A. The next seven months gave us data that no spreadsheet could have supplied.
We had three rapid response activations and two unplanned ICU transfers. Finance estimated the incremental cost at just under $50,000.
One of those cases was the exact scenario above: a patient on patient-controlled analgesia and supplemental oxygen, with a normal SpO2 at the 2 a.m. spot check — but a respiratory rate of six breaths per minute. The patient spent six days in the ICU. The incremental cost of that single event was roughly $18,000, which is more than the annual service contract on six monitors, by the way.
I am not claiming continuous monitoring would have prevented every event. But the clinical team was explicit: in two of the three rapid responses, the patient had been on supplemental oxygen, which delayed the point where pulse oximetry reflected the problem.
When I re-ran my model with those events included, the $91,000 capital cost stopped looking like an expense. It looked like insurance that paid for itself by preventing one event per year.
What about the hematology analyzer?
Honestly, the analyzer was the item I nearly cut from the proposal to get the budget down.
The economics of point-of-care hematology are counterintuitive. The analyzer's reagent and consumable cost per test is higher than the central lab's fully loaded cost per test. If you compare only 'cost per CBC,' the analyzer loses.
But that's the wrong comparison. The analyzer isn't replacing a lab test; it's replacing a delay. For a post-operative patient with a dropping hemoglobin, waiting 45 minutes for a central lab result is long enough for anemia to become instability. A three-minute bedside result changes the response.
The risk, of course, was committing to a device whose per-test cost was higher than the lab's. The upside was earlier detection of bleeding that might otherwise progress. I ran that tradeoff back and forth for a week. In the end, the clinical team's argument won: the analyzer wasn't about saving money per test; it was about changing the trajectory for one or two patients a year.
Which option won?
After seven months of pilot data, we bought the Option B equipment.
The conclusion wasn't 'continuous monitoring is always worth it.' It was: for a patient population with respiratory risk, opioid use, and potential for rapid deterioration, scheduled spot checks were not adequate — and inadequate monitoring has a cost.
Would I make the same call for a low-acuity med-surg unit or a short-stay observation unit? Probably not. If your patients are stable and their lengths of stay are measured in hours, portable spot-check vital signs monitors are often a perfectly reasonable choice. The mistake isn't choosing spot checks. The mistake is choosing them for a unit that is supposed to catch deterioration early.
So if you're doing this analysis for your own facility, start with the patient population, not the price list. Then compare configurations using tools like the Smiths Medical official website or catalog; both will help you see the accessory and consumable requirements rather than just the monitor's sticker price. And build a cost model that includes your finance team's internal cost per unplanned ICU transfer. That last number is the one that changed our decision.
Bottom line? The cheapest option in the capital budget can be the most expensive one in patient outcomes. That sounds like a slogan, but it's the actual conclusion in our cost tracking system.
